Medpace Holdings, Inc.
- Jurisdiction
United States - LEI
549300H8TYEUVTW14A54 - ISIN
US58506Q1094 (MEDP )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€217.15 109.3% overvalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. Read full profile
Fundamentals
- Net revenue
€1.90B - Gross margin
31.6% - EBIT
€407.29M - EBIT margin
21.4% - Net income
€356.79M - Net margin
18.7%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| BURWIG SUSAN E | Exec. VP, Operations |
|
|
|
|
| Troendle August J. | CEO |
|
|
|
|
| Troendle August J. | CEO |
|
|
|
|
| McCarthy Cornelius P. III | N/A |
|
|
|
|
| BURWIG SUSAN E | Exec. VP, Operations |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Lisa McClain | September 12, 2025 | $1.00K–$15.00K |
| David Taylor | September 2, 2025 | $1.00K–$15.00K |
| Gilbert Cisneros | August 14, 2025 | $1.00K–$15.00K |
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
| Robert Bresnahan | February 13, 2025 | $1.00K–$15.00K |
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
| François Rochon |
|
|
|
Buy |
| James Anderson |
|
|
|
Sell |
Earnings Calls
Latest earnings call: April 23, 2024 (Q1 2024)